111In-CP-04

N/A

Report date: 2025/11/20 16:00:44
NME

Base Information

Drug Name111In-CP-04
Drug Alias Name111In-CP04 (DOTA-(DGlu)6-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2111In-CP-04CP-04-[111In]Indium-111-CP-04[111In]In-CP04
ClassificationRadiation-emitting products > Nuclides > Indium > 111InRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates +[4] 
Mechanisms of ActionCholecystokinin B receptor modulators
TargetsCholecystokinin B receptor
Therapy Area/IndicationsMedullary thyroid cancer (MTC)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryPolandNetherlandsSlovenia +[6] 
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesJagiellonian University Sylff Fellows Association
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAzienda Ospedaliero Universitaria PisanaJagiellonian University Sylff Fellows Association
Active IndicationsN/A
Inactive IndicationsMedullary thyroid cancer (MTC)

Other Information

ATC CodeN/A
Related LinksN/A